Celularity Inc. (NASDAQ:CELUW – Get Free Report) was the target of a significant increase in short interest in April. As of April 30th, there was short interest totaling 3,342 shares, an increase of 350.4% from the April 15th total of 742 shares. Based on an average trading volume of 7,256 shares, the short-interest ratio is presently 0.5 days.
Celularity Stock Performance
Shares of CELUW stock traded up $0.00 during mid-day trading on Friday, reaching $0.01. 167 shares of the company’s stock traded hands, compared to its average volume of 17,465. Celularity has a 12 month low of $0.01 and a 12 month high of $0.08. The company’s 50-day moving average price is $0.01 and its 200-day moving average price is $0.01.
Celularity Company Profile
Celularity, Inc is a clinical-stage biotechnology company headquartered in Florham Park, New Jersey, that specializes in the development and commercialization of allogeneic “off-the-shelf” cell therapies derived from postpartum placental cells. Leveraging a proprietary platform of placental- and umbilical-derived cells, the company seeks to deliver immune-modulatory, regenerative and anti-inflammatory treatments across oncology, immunology and other therapeutic areas. By harnessing the natural properties of placental cells, Celularity aims to overcome the limitations of autologous therapies and scale production to serve a broad patient population.
The company’s pipeline includes CYNK-001, an investigational natural killer (NK) cell therapy being evaluated for hematological malignancies and solid tumors, as well as other cell-based programs targeting viral infections and tissue repair.
See Also
- Five stocks we like better than Celularity
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.
